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The aim of this paper is to describe and compare components of diagnostic delay (patient, primary care, referral, secondary care) for
six cancers (breast, colorectal, lung, ovarian, prostate and non-Hodgkin’s lymphoma), and to compare delays in patients who saw their
GP prior to diagnosis with those who did not. Secondary data analysis of The National Survey of NHS Patients: Cancer was undertaken
(65192 patients). Breast cancer patients experienced the shortest total delays (mean 55.2 days), followed by lung (88.5), ovarian
(90.3), non-Hodgkin’s lymphoma (102.8), colorectal (125.7) and prostate (148.5). Trends were similar for all components of delay.
Compared with patient and primary care delays, referral delays and secondary care delays were much shorter. Patients who saw their
GP prior to diagnosis experienced considerably longer total diagnostic delays than those who did not. There were significant
differences in all components of delay between the six cancers. Reducing diagnostic delays with the intention of increasing the
proportion of early stage cancers may improve cancer survival in the UK, which is poorer than most other European countries.
Interventions aimed at reducing patient and primary care delays need to be developed and their effect on diagnostic stage and
psychological distress evaluated.
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There is good evidence that UK patients’ cancers are diagnosed at a
more advanced stage compared with patients in other European
countries (Berrino et al, 2001); this may partly explain the poorer
survival of UK cancer patients. Reducing diagnostic delays may
increase the proportion of early stage cancers and improve
survival. Delays may occur at different stages of the cancer
diagnostic journey: ‘patient delay’ (from onset of symptoms to
their first presentation); ‘primary care delay’ (from first presenta-
tion in primary care to referral for further care or diagnostic
investigation); ‘referral delay’ (from referral for further care or
diagnostic investigation to being seen in secondary care); and
‘secondary care delay’ (from being first seen in secondary care to
diagnosis). Patients diagnosed through screening bypass patient
and primary care delays. Current UK policy aimed at earlier
detection of cancer by reducing delays concentrates mainly on
treatment and referral delays (DoH, 2000a,b), although the
evidence base for these policies has been questioned (Jones et al,
2001).
The literature regarding the length of diagnostic delays has
several common themes. With the exception of cancer registry
studies, most of the studies report conflicting findings from
relatively small numbers of patients; generalisation from these data
is difficult. This is compounded by different healthcare settings,
different methods of measuring delays, the potential confounding
effect of lead-time bias, and variations between cancers;
and is reflected in the conflicting findings from this literature.
Data from the literature relating to delays are shown in Table 1.
The effect of delays on clinical outcomes varies between cancers.
In breast cancer, delays of 3–6 months are associated with
poorer survival (Richards et al, 1999), although some patients
who present early may have poorer outcomes (Sainsbury et al,
1999). In colorectal cancer, delays have not been shown to have an
effect on survival (Roncoroni et al, 1999), and although somewhat
inconclusive, shorter delays have been associated with earlier
stage diagnosis for rectal but not for colonic tumours (Arbman
et al, 1996; Kiran and Glass, 2002). In lung cancer, there is
some evidence that early stage disease has better survival
(Mountain, 1997), although there is wide variation in the findings
of reported studies (Jensen et al 2002; Moody et al, 2004; Myrdal
et al, 2004). In ovarian cancer, there is no evidence that delays in
referral or diagnosis affects survival at 18 months (Kirwan et al,
2002), although women with earlier stage disease are diagnosed
faster (Wikborn et al, 1996). We are not aware of any studies that
have examined the effect on diagnostic delay of seeing the GP prior
to a cancer diagnosis compared with not seeing the GP (whether by
a screening, or in-patient diagnosis following an emergency
admission or via A&E). For some cancers, especially lung,
morbidity and psychological outcomes may be more important
than mortality. Psychological distress correlates positively with
total diagnostic delay (Risberg et al, 1996), itself a reason to
minimise delays.
The aim of this paper is to describe and compare the
components of diagnostic delay (patient, primary care, referral,
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ssecondary care) for six types of cancer (breast, colorectal, lung,
ovarian, prostate or non-Hodgkin’s lymphoma), using patient-
reported data from the National Survey of NHS Patients: Cancer.A
secondary aim is to compare delays in those patients who reported
seeing their GP prior to diagnosis with those who bypassed their
GP, for whatever reason.
MATERIALS AND METHODS
Section 1 – National Survey of NHS Patients: cancer
The National Survey of NHS Patients: Cancer assessed quality of
care of hospital patients in 172 Trusts in England (DoH, 2002).
Table 1 Diagnostic delays in six cancers – summary of findings from the literature
Total delays Patient delays Primary care delays Referral delays
Secondary care
delays Other
Breast 15 days (Arndt
et al, 2003)
0 days (Jones et al,
1992)
4 weeks (Thongsuksai
et al, 2000)
1/4 412 weeks
(Thongsuksai, 2000)
1 Week (Thulesius et al,
2004)
14 days (Meechan et al,
2002)
16 days (Arndt et al,
2002)
13 days (Nosarti et al,
2000)
— 13 days (Sainsbury et al,
1999)
11 days (Jones et al,
1992)
9 days (urgent referrals)
(Spurgeon et al, 2000)
14 days (nonurgent
referrals) (Spurgeon
et al, 2000)
13 days (Nosarti et al,
2000)
— 1/3 experience total
pre-hospital delays of
412 weeks (Richards
et al, 1999)
Provider delay of 1
Week (Thulesius et al,
2004)
Colorectal - 60 days (Aithal and
Tanner, 1996)
27.5 days (Thongsuksai
et al, 2000)
46 weeks (54%)
(Robinson et al, 1986)
16.2 days (mean,
rectum) (Holliday and
Hardcastle, 1979)
12.7 days (mean, colon)
(Holliday and
Hardcastle, 1979)
20–66%) 43 months
(Graffner and Olsson,
1986)
47%46 weeks
(Robinson et al, 1986)
15.3 days (mean,
rectum) (Holliday and
Hardcastle, 1979)
11.2 days (mean, colon)
(Holliday and
Hardcastle, 1979)
20–34% 43 months
(Holliday and
Hardcastle, 1979)
16 days (Aithal and
Tanner, 1996)
11 days (Jones et al,
1992)
13 days (urgent referrals)
(Spurgeon et al, 2000)
27 days (nonurgent
referrals) (Spurgeon
et al, 2000)
15 days (Aithal and
Tanner, 1996)
17 days (mean 52)
(Potter and Wilson,
1999)
Mean delay to
treatment delay: 244
days (Rectal), 149 days
(colon) (Langenbach
et al, 2003)
Lung 4.6 months (mean
5.8) (Myrdal et al,
2004)
189 days (Koyi et al,
2002)
109 days (Billing
and Wells, 1996)
21 days (mean 43)
(Koyi et al, 2002)
31 days (Jones et al,
1992)
33 days (mean 56) (Koyi
et al, 2002)
7 days (Jones et al, 1992)
7 days (urgent referrals)
(Spurgeon et al, 2000)
12 days (nonurgent
referrals) (Spurgeon
et al, 2000)
9 days (mean 33)
(Koyi et al, 2002)
1.6 months (Myrdal
et al, 2004)
19 (8.6%) total delay
41 year (of whom 18
had adenocarcinoma)
(Yoshimoto et al, 2002)
Ovarian 55% o3 months,
26% 46 months,
and 11% 412
months (Goff et al,
2000)
56% o4 weeks,
30% 48 weeks,
and 4% o4 days
(Wikborn et al,
1996)
78% o4 weeks (Kirwan
et al, 2002)
3.5 weeks (Thulesius
et al, 2004)
73% o4 weeks (Kirwan
et al, 2002)
6 days (Kirwan et al,
2002) 70% o2 weeks
(Kirwan et al, 2002)
6 days (urgent referrals)
(Spurgeon et al, 2000)
24 days (nonurgent
referrals) (Spurgeon
et al, 2000)
— Mean total pre-hospital
delay 95.3 days (s.d.
15.1 days) (Kirwan et al,
2002)
Provider delay of 3.5
weeks (Thulesius et al,
2004)
Prostate — 20 days (Jones et al,
1992)
— 15 days (Jones et al,
1992)
19 days (urgent referrals)
(Spurgeon et al, 2000)
41 days (nonurgent
referrals) (Spurgeon
et al, 2000)
—
NHL — — — — —
All delays are medians unless other stated.
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sPatients with one of six types of cancer (breast, colorectal, lung,
ovarian, prostate or non-Hodgkin’s lymphoma) discharged from
hospital between July 1999 and June 2000, participated in the
survey. From a total sample of 123984 patients, 92683 were sent a
questionnaire, after excluding those patients whose death had been
registered. Completed questionnaires were returned by 65337
patients. This represented a response rate of 74%, after allowing
for returned mail, patients whose death had been reported after
mailing and ineligible patients. In the sample, 65192 were
diagnosed with one of six types of cancer: female breast cancer
(25627), colorectal (15891), prostate (10992), non-Hodgkin’s
lymphoma (5604), lung (4011) and ovarian (3067). A total of
145 male patients with breast cancer also participated in the survey
but were not included in this analysis because of their small
numbers. The data set was obtained from the Data Archive at the
University of Essex in 2003. Part D of the questionnaire asked a
series of questions devoted to ‘finding out what was wrong with
you’ (Box 1).
Section 2 – Calculating components of delays, exclusions,
and assumptions
Delays were calculated differently for patients who reported
visiting their GP prior to diagnosis and those who had not,
because of ways in which the questions were asked. This process is
highlighted in Figure 1.
Total prehospital delay This was calculated as the number of
days between the date of appointment with hospital doctor (Q D5)
and the date that symptoms were first noticed (Q D1). These were
both asked as month and year. The first of the stated month was
used for calculations. Total prehospital delays could not be
calculated for patients whose first appointment with a hospital
doctor was before the date they first noticed symptoms, or if one
or both dates were missing. For those patients who did not see
their GP prior to diagnosis, the ‘total prehospital delay’ is
equivalent to ‘patient delay’ since there were neither primary care
nor referral delays.
Referral delay Referral delay was derived from Q D3, a
categorical response variable, and was calculated by assigning a
mid-point to the categories used (see Box 2). Referral delays could
not be calculated for: patients who could not have had any referral
delay because they did not see their GP prior to their diagnosis (i.e.
answered no to Q D2, or did not answer Q D2); patients who had a
delay of more than 1 year, since the categorisation did not permit
calculation; and those who did not respond or could not
remember.
Patient and primary care delay
For patients who saw their GP prior to diagnosis, patient and
primary care delays were calculated by subtracting the referral
delay (as above), from the total prehospital delay (as above).
Patient and primary care delays could not be calculated if the
referral delay or the total prehospital delay was not available, or if
the referral delay was longer than the prehospital delay, giving a
false-negative patient and primary care delay. This arose because
of the assumptions of mid-points and first of the month as
described above.
Secondary care delay This was calculated from question Q D9 (a
categorical response variable), which asked when the patient found
out their diagnosis. As with Q D3, the number of days was
calculated by assigning a mid-point to the categories (Box 2).
Secondary care delays could not be calculated for patients who
responded ‘before first appointment’ or ‘more than 6 months’, or
those who ‘had not been told’ or did not answer.
Total diagnostic delay Total diagnostic delay was calculated by
adding total prehospital delay to secondary care delay. As
described above, this excludes patients who were diagnosed either
before or more than 6 months after their first hospital appoint-
ment. Total delays could not be calculated if either secondary care
delay or prehospital delay was missing.
Section 3 – statistics
Diagnostic delay between the six cancer groups were compared
using Kruskall–Wallis tests; w
2 tests were used for the categorical
data. Mann–Whitney tests were used for comparisons within each
cancer group between those patients who saw a GP and those who
did not. A P-value of o0.05 was used to indicate statistical
significance. All analyses were performed on SPSS (Version 11).
The data are interval scale data; means and standard deviations
(s.d.) are presented. However, due to the skewed nature of some of
the distributions medians and interquartile ranges (IQR) are also
presented for completeness. Confidence intervals around the
means were calculated and are presented where appropriate in
the figures. The large variation in delays resulted in some negative
lower limits and large upper limits for some of the categories; these
are not presented in the tables.
RESULTS
Numbers of patients seeing their GP prior to diagnosis
A total of 52079 (80%) patients reported visiting their GP before
their diagnosis, 12074 (18%) reported that they had not, and 1039
Box 1 Questions analysed in this paper
K Q D1: When did you first notice signs or symptoms? (month and year)
K Q D2: Had you visited a GP about this condition before you attended
hospital? (Yes/No)
K Q D3: (if answered Yes to D2) After visiting the GP, how long did you
have to wait before your first appointment with a hospital doctor
(predetermined categories, including cannot remember)?
K Q D5: When did you first see a hospital doctor for your condition?
(month and year)
K Q D9: Were you told what was wrong with you during this first hospital
appointment, or was it before or after this first hospital appointment? If told
after this appointment, then when? (predetermined categories including NA)?
Box 2 Mid-point calculations for categorical variables
Referral delay Secondary care delay
Category Mid-point
number of days
Category Mid-point
number of days
Same or next day 1 day Before first
appointment
Unable to
estimate
2 days–1 week 5 days Told at first
appointment
0 days
1–2 weeks 11 days 1 day to 2 weeks 7 day
2 weeks–1
month
21 days 2 weeks to 1
month
21 days
1–3 months 56 days 1 month to 3
months
56 days
3–6 months 126 days 3 months to 6
months
126 days
6 months–1 year 252 days 4 6 months Unable to
estimate
41 year Unable to
estimate
‘not been told’ Unable to
estimate
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sA     For those who saw a GP (52079)
First symptom  Contact with GP  Hospital doctor   Diagnosis 
Q D1 (date) Q D2 (yes) Q D5 (date) Q D9 (date)
B     For those who did not see a GP (12 074) 
First symptom  Contact with GP  Hospital doctor    Diagnosis 
Q D1 (date) (yes/no) Q D5 (date) Q D9 (date) 
C     For those who did not answer Q D2 (1039) 
First Hospital doctor   Diagnosis 
Q D1 (date)  Q D5 (date) Q D9 (date)
Total prehospital delay 
(Q D1− Q D5)
n= 44 028
Referral delay (Q D3) 
n=47 451
Secondary care 
delay 
(Q D9) 
n=42 221
Patient and primary care 
delay
(Q D1− Q D5) – D3 
n= 38 707
Total delay 
(Q D1− Q D5) +  Q D9 
n=37 063
Patient delay
(Q D1− Q D5)
n= 9743
Secondary care 
delay
(Q D9)
n=9827
Total delay
(Q D1− QD5) + Q D9
n= 8164
Total pre-hosp delays
(either patient or patient + primary care delays)
(Q D1− Q D5)
n= 239
Secondary care
delay
(Q D9)
n=551
Total delay 
(Q D1− Q D5) + Q D9 
n= 180
symptom
Figure 1 Individual components of delay in diagnosis.
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s(2%) did not answer this question. There was variation between
the cancers, with 27% of breast cancer patients, but only 10%
colorectal cancer patients, not seeing their GP prior to diagnosis
(Table 2). In order to investigate this further, a sensitivity analysis
was conducted, for breast cancer, to compare data for women
within the screening age range (50–64) with women outside this
age range. In all, 58% of the screening age women saw their GP,
compared with 84% for those outside the screening age.
Main findings
The numbers of patients for whom different components of
delay were calculated are shown in Table 3. Table 4 shows
the mean (s.d.) and median (IQR) for each component of
diagnostic delay by cancer type. There were significant differences
for all the components of delay between the six site-specific
cancers (Table 5).
Table 2 Number and percentage of patients seeing their GP prior to attending hospital
Colorectal Lung Ovarian Prostate Non-Hodgkin’s lymphoma Breast Total
n % n % n % n % n % n % n %
Did see GP 14032 88 3246 81 2638 86 9159 83 4742 85 18262 71 52079 80
Did not see GP 1612 10 694 17 395 13 1560 14 791 14 7022 27 12074 19
Not answered 247 2 71 2 34 1 273 3 71 1 343 1 1039 2
Total 15891 4011 3067 10992 5604 25627 65192
Table 3 Summary of the number of patients excluded, and those available for analysis for each component of diagnostic delay, by cancer type
Colorectal Lung Ovarian Prostate NHL Breast Total
Number in the sample 15891 4011 3067 10992 5604 25627 65192
Total delay 11385 (72%) 2669 (67%) 2216 (72%) 5840 (53%) 3537 (63%) 19760 (77%) 45407 (70%)
Secondary delay or total prehospital delay missing 4506 1342 851 5152 2067 5867 19785
15891 4011 3067 10992 5604 25627 65192
Total delay (if ‘yes’ to Q D2) 10248 2235 1943 4909 3049 14679 37063
Secondary delay or total pre-hospital delay missing 3784 1011 695 4250 1693 3583 15016
14032 3246 2638 9159 4742 18262 52079
Total delay (if ‘no’ to Q D2) 1094 420 267 896 479 5008 8164
Secondary delay or total pre-hospital delay missing 518 274 128 664 312 2014 3910
1612 694 395 1560 791 7022 12074
Total delay (if no response to Q D2) 43 14 6 35 9 73 180
Secondary delay or total pre-hospital delay missing 204 57 28 238 62 270 859
247 71 34 273 71 343 1039
Total pre-hospital delay 13174 (83%) 3260 (81%) 2673 (87%) 7759 (71%) 4650 (83%) 22494 (88%) 54010 (83%)
First appointment before had symptoms 453 158 65 382 168 507 1733
One or both dates missing 2264 593 329 2851 786 2626 9449
15891 4011 3067 10992 5604 25627 65192
Total pre-hospital delay (if ‘yes’ to Q D2) 11835 2706 2330 6563 4033 16561 44028
First appointment before had symptoms 388 134 53 320 112 319 1326
One or both dates missing 1809 406 255 2276 597 1382 6725
14032 3246 2638 9159 4742 18262 52079
Patient delay (if ‘no’ to Q D2) 1282 535 336 1146 605 5839 9743
One or both dates missing 275 135 48 354 130 999 1941
First appointment before had symptoms 55 24 11 60 56 184 390
1612 694 395 1560 791 7022 12074
Total prehospital delay (if no response to Q D2) 57 19 7 50 12 94 239
First appointment before had symptoms 10 0 1 2 0 4 17
One or both dates missing 180 52 26 221 59 245 783
247 71 34 273 71 343 1039
Patient and primary care delay (if ‘yes’ to Q D2) 10026 2361 2036 5369 3447 15468 38707
Referral delay or total prehospital delay missing 2959 675 407 3065 951 2076 10133
False negatives 1047 210 195 725 344 718 3239
14032 3246 2638 9159 4742 18262 52079
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s1. Total diagnostic delay
Breast cancer patients experienced the shortest mean and median
delays, followed by lung, ovarian, non-Hodgkin’s lymphoma,
colorectal and prostate. Delays were considerably shorter in all
cancers for those patients who did not report seeing their GP prior
to diagnosis (Figure 2). There was a significant difference in
total diagnostic delay between those patients who saw their GP
and those who did not for colorectal (t(11340)¼6.9, Po0.001),
lung (t(2653)¼4.7, Po0.001), ovarian (t(2208)¼2.9, P¼0.004),
prostate (t(5803)¼4.2, Po0.001), non-Hodgkin’s lymphoma
(t(3526)¼6.6, Po0.001) and breast (t(19685)¼7.9, Po0.001).
In each case, those who saw their GP had a longer delay than those
who did not.
2. Prehospital delays
Some patients in each cancer group reported no delay from first
noticing symptoms until they saw a hospital doctor: breast 10601
out of 22494 (47%), lung 1177 out of 3260 (36%), ovarian 932 out
of 2673 (35%), non-Hodgkin’s lymphoma 1628 out of 4650 (35%),
prostate 2391 out of 7759 (31%), and colorectal 3467 out of 13174
(26%). There was a significant difference between cancer groups
(w
2(5)¼1765.0, Po0.0001).
2a. Total prehospital delays The total prehospital delays were
analysed by those who saw a GP prior to diagnosis and those who
did not, since they are measuring different processes in each case
(Figure 3). There was a significant difference in total prehospital
delay between those patients who saw their GP and those who did
not for all cancers: colorectal (t(13114)¼6.4, Po0.001); lung
(t(3239)¼3.9, Po0.001); ovarian (t(2664)¼3.3, P¼0.001); pros-
tate (t(7707)¼3.9, Po0.001); non-Hodgkin’s lymphoma
(t(4636)¼4.3, Po0.001); and breast (t(22398)¼8.7, Po0.001).
In each case, those who saw their GP had a longer delay than those
who did not.
2b. Patient and primary care delays The shortest delays were
experienced by patients with breast cancer, followed by lung,
ovarian, non-Hodgkin’s lymphoma, colorectal and prostate
(Figure 4).
2c. Referral delays The shortest delays were experienced by
patients with breast cancer, followed by lung, ovarian, non-
Table 3 (Continued)
Colorectal Lung Ovarian Prostate NHL Breast Total
Referral delay 12527 (79%) 2950 (74%) 2453 (80%) 7877 (72%) 4242 (76%) 17402 (68%) 47451 (73%)
Answer ‘no’ to Q D2 1612 694 395 1560 791 7022 12074
No response to Q D2 247 71 34 273 71 343 1039
Can’t remember (Q D3) 777 186 78 838 285 474 2638
Not answered (Q D3) 371 71 56 200 104 227 1029
4 1 year (Q D3) 357 39 51 244 111 159 961
15891 4011 3067 10992 5604 25627 65192
Secondary care delay 13244 (83%) 3199 (80%) 2474 (81%) 7671 (70%) 4073 (73%) 21938 (86%) 52599 (81%)
Not answered 690 159 112 606 242 622 2431
Not told 166 26 20 95 47 68 422
4 6 months 266 38 30 173 68 137 712
Told before 1048 457 295 1251 420 1729 5200
NA 477 132 136 1196 754 1133 3828
Total 15891 4011 3067 10992 5604 25627 65192
Secondary care delay (if ‘yes’ to Q D2) 11801 2633 2145 6393 3448 15801 42221
Not answered 505 95 83 390 164 385 1622
Not told 147 20 19 69 43 47 345
4 6 months 251 34 29 151 64 115 644
Told before 906 348 244 1112 343 981 3934
NA 422 116 118 1044 680 933 3313
Total 14032 3246 2638 9159 4742 18262 52079
Secondary care delay (if ‘no’ to Q D2) 1314 532 308 1143 589 5941 9827
Not answered 90 39 19 115 51 134 448
Not told 18 6 1 24 4 19 72
4 6 months 12 4 1 21 4 21 63
Told before 133 98 48 119 72 722 1192
NA 45 15 18 138 71 185 472
Total 1612 694 395 1560 791 7022 12074
Secondary care delay (if no response to Q D2) 129 34 21 135 36 196 551
Not answered 95 25 10 101 27 103 361
Not told 1 0 0 2 0 2 5
4 6 months 3 0 0 1 0 1 5
Told before 9 11 3 20 5 26 74
NA 10 1 0 14 3 15 43
Total 247 71 34 273 71 343 1039
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patients with breast cancer were seen within 2 weeks, compared
with less than 30% prostate cancer patients.
3. Secondary care delay
These delays were considerably shorter than referral and
prehospital delays (Figures 6 and 7). In all 9% found out their
diagnosis prior to their first hospital appointment, but this varied
significantly between cancer groups. Delays were shortest for
breast cancer, followed by ovarian, prostate, lung, colorectal and
non-Hodgkin’s lymphoma. The median number of days was zero
for all six cancer groups; the majority of patients found out
their diagnosis at their first hospital appointment. Patients who
saw their GPs prior to diagnosis had longer secondary care delays
than those who did not. There was a significant difference for each
cancer group: colorectal (t(13113)¼6.6, Po0.001); lung
(t(3163)¼5.8, Po0.001); ovarian (t(2451)¼3.6, Po0.001); pros-
tate (t(7534)¼7.5, Po0.001); non-Hodgkin’s lymphoma
(t(4035)¼7.5, Po0.001); and breast (t(21740)¼8.2, Po0.001).
In each case, those who saw their GP had a longer delay than those
who did not.
Table 4 Summary of the components of diagnostic delay by cancer type (all data in days)
Colorectal Lung Ovarian Prostate NHL Breast
(1) Total delay
All patients
Mean (s.d.) 125.7 (395.2) 88.5 (239.8) 90.3 (320.0) 148.5 (494.3) 102.8 (256.7) 55.2 (241.8)
Median (IQR) 61 (29–143) 38 (7–91) 37 (7–92) 61 (7–126) 51 (7–117) 30 (0–38)
GP patients
Mean (s.d.) 134.4 (413.5) 98.3 (247.5) 97.7 (338.5) 160.5 (437.7) 114 (273.2) 63 (258.9)
Median (IQR) 67 (30–151) 51 (21–99) 50 (7–99) 61 (30–150.5) 56 (21–122) 31 (0–56)
Non-GP patients
Mean (s.d.) 46.9 (124.5) 38.1 (190.5) 37.9 (113) 85.6 (733.5) 31.2 (74.8) 31.8 (176.9)
Median (IQR) 7 (0–52) 0 (0–31) 7 (0–31) 0 (0–31) 0 (0–31) 7 (0–31)
No response to D2
Mean (s.d.) 62.6 (103.3) 31.4 (47.8) 20.5 (37.2) 75.1 (99.6) 98.2 (136.8) 76.4 (387.7)
Median (IQR) 21 (0–86) 7 (0–45) 0 (0–46.3) 31 (0–122) 7 (0–180.5) 7 (0–31)
(2a) Total prehospital delay
All patients
Mean (s.d.) 116.7 (424.9) 79.1 (264.8) 83.1 (306.6) 141.7 (505.5) 99.7 (344.8) 52.2 (249.5)
Median (IQR) 59 (0–122) 31 (0–62) 31 (0–91) 31 (0–121) 31 (0–92) 29 (0–31)
GP patients
Mean (s.d.) 124.8 (440.8) 87.6 (276.9) 90.7 (325.4) 151.5 (456.4) 107.9 (341.6) 60.8 (271.5)
Median (IQR) 61 (30–122) 31 (0–91) 31 (0–92) 61 (29–122) 31 (0–92) 30 (0–31)
Non-GP patients (¼patient delay)
Mean (s.d.) 44.3 (234.5) 38.2 (193.6) 32.1 (102.4) 88.5 (730.2) 43.7 (361.5) 27.7 (167.5)
Median (IQR) 0 (0–31) 0 (0–30) 0 (0–31) 0 (0–30) 0 (0–29) 0 (0–30)
(2b) Patients & primary care delay (GP patients)
Mean (s.d.) 80.4 (393.9) 51.8 (187.1) 58.1 (327.9) 97.5 (379.2) 58.6 (244.5) 40.4 (245.9)
Median (IQR) 20 (0–66) 10 (0–40) 10 (0–40) 10 (0–66) 10 (0–40) 9 (0–20)
(2c) Referral delay (GP patients)
Mean (s.d.) 42.8 (54.7) 33.1 (48.6) 34.8 (51.4) 50.0 (57.1) 37.2 (53.1) 20.8 (30.7)
Median (IQR) 21 (11–56) 21 (5–56) 11 (5–56) 21 (11–56) 21 (5–56) 11 (5–21)
(3) Secondary care delay
All patients
Mean (s.d.) 11.9 (24.7) 11.5 (23.0) 8.7 (20.4) 11.3 (25.2) 13.2 (25.2) 5.4 (13.5)
Median (IQR) 0 (0–7) 0 (0–7) 0 (0–7) 0 (0–7) 0 (0–21) 0 (0–7)
GP patients
Mean (s.d.) 12.4 (24.2) 12.6 (23.9) 9.3 (21.2) 12.2 (25.9) 14.5 (26.4) 5.9 (14.3)
Median (IQR) 0 (0–7) 0 (0–21) 0 (0–7) 0 (0–7) 0 (0–21) 0 (0–7)
Non-GP patients
Mean (s.d.) 7.7 (20.4) 6.3 (16.5) 4.8 (13.8) 6.2 (19.6) 6.1 (15.8) 4.2 (10.4)
Median (IQR) 0 (0–7) 0 (0–7) 0 (0–7) 0 (0–0) 0 (0–7) 0 (0–7)
No-response D2
Mean (s.d.) 6.4 (14.3) 7.8 (23.6) 6.7 (17.1) 10.5 (27.2) 5.6 (13.8) 5.3 (17.9)
Median (IQR) 0 (0–7) 0 (0 – 2) 0 (0–0) 0 (0–7) 0 (0–5) 0 (0–0)
Table 5 Kruskall–Wallis statistical tests comparing the six cancer groups
Delay type v
2 df P-value
Total prehospital delay 3859.9 5 o0.001
Patient, primary care and referral delay (GP
patients only)
3172.5 5 o0.001
Patient delay (non-GP patients only) 17.2 5 0.004
Patient and primary care delay (GP patients
only)
1490.4 5 o0.001
Referral delay (GP patients only) 2910.0 5 o0.001
Secondary care delay 572.9 5 o0.001
Total delay 3632.0 5 o0.001
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sAssessing the effect of assumptions made in main data
analysis
Referral delay was greater than 1 year for 2% of the sample;
these were excluded from the main analysis. Similarly,
1% of patients with a secondary care delay of greater than 6
months were excluded from the main analysis. In order to
determine the effect of this on the analysis, we reanalysed the
data, coding delays of greater than 1 year as 365 days and delays
of 6 months as 168 days. This showed that the mean delay
increased, as would be expected, but that the median delays
remained the same for all except referral delay for ovarian
cancer, where there was an increase from 11 days to 21 days
(Table 6).
DISCUSSION
Statement of principal findings
This paper reports findings from the analysis of a large data set of
patients relating to their cancer diagnosis, and is the largest single
comprehensive study of diagnostic delays in cancer. It is one of few
studies to report delays in prostate cancer and the first to do so in
non-Hodgkin’s lymphoma. Total diagnostic delays remain long,
particularly in some cancers. Breast cancer patients had the
shortest delays compared with the other cancers. The mean delay
of 8 weeks still suggests that the diagnostic process could be faster.
Prostate cancer had the longest delays compared with the other
cancers. Of more concern are the lengthy delays for colorectal
cancer. Patients with lung cancer, ovarian cancer and non-
Hodgkin’s lymphoma also experienced considerable delays.
Patient and primary care delays contributed to larger proportions
of the total diagnostic delay than did referral delays and secondary
care delays. Over a third of the sample reported no prehospital
delays, either because there were no delays (i.e. cancer found by
screening, or asymptomatic tumours found while under investiga-
tion for other problems) or because the symptom and the first
hospital visit occurred within the same month. Large differences
were found in all components of delay between patients who
reported seeing their GP prior to diagnosis and those who did not
(diagnosed through screening or diagnosed while an in-patient)
with patients who reported seeing their GP experiencing longer
delays.
Strengths and weaknesses of the study All self-report question-
naires have to be interpreted with some caution. Sampling in 172
NHS Trusts in England ensured generalisability. There is the
potential for bias in that different proportions of patients between
the six cancer groups would have died prior to questionnaire
administration; furthermore, these patients are likely to have had
more aggressive disease and to have presented differently to those
who survived. There is the potential for recall bias, especially given
the time interval between diagnosis and survey completion, for at
least some of the sample. Data were not collected relating to
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Figure 2 Total diagnostic delay (GP vs non-GP).
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Figure 3 Total prehospital delay (patient, primary care and referral delay
for GP patients and patient delay for non-GP patients).
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sdiagnostic stage, comorbidity, histological type of cancer, or the
natural history of the cancer; hence, we cannot be sure that the
sample was representative of the ‘cancer population’, and cannot
exclude the possibility of confounding as a result.
The ways in which questions were asked forced us to make
assumptions about the data; these may have affected some
of the analyses. For example, time was calculated by using the
first of each month as the reference date for ‘MM/YY’ variables. If
patients experienced symptoms during the same month that they
were first seen at the hospital, this time duration would have been
recorded as zero. However, this should give rise to a neutral effect
because patients who experienced symptoms at the end of a month
and were seen at the hospital at the beginning of the next month
would have a time duration recorded as 2 months. As a result of
‘open-ended’ time categories, patients with referral delays of
greater than 1 year and with secondary care delays greater than 6
months were excluded. This only affected a small number of
patients and did not influence the main findings. There may be
some differences between the actual date of ‘tissue diagnosis’ and
the date perceived by the patients as the date that they were told
‘what was wrong with them’. However, this would have been
consistent across the data set. Our analysis divided patients who
had reported seeing their GP for ‘this condition’ prior to diagnosis
with those who did not. The survey did not ask patients about
alternative routes into diagnosis, we are not therefore able to
comment further on this. Lastly, the survey did not ask questions
in such a way to permit patient and primary care delays to be
calculated separately.
Strengths and weaknesses in relation to other studies, discussing
important differences in results Compared with previous
studies of diagnostic delay in cancer, this paper reports data
from a very large data set. There is no standard tool for asking
patients about their delays; hence, comparisons between all
such studies must be undertaken with caution. In breast cancer,
our data show that delays were longer than most previously
published reports. For prostate cancer, there are no previous
data with which to compare total delays, but our data on referral
delays are in keeping with previous data. For colorectal cancer,
our figures show that referral delays were longer than other
published data, but secondary care delays were shorter. Our
figures for lung cancer compare favourably with the literature,
with total delays, referral delays and secondary care delays
all being shorter. Our figures for referral delay in ovarian cancer
show slightly longer referral delays. We are not aware of any
other work that has compared delays between patients who saw
their GP prior to diagnosis, with those diagnosed via alternative
pathways.
Meaning of the study: possible explanations and implications for
clinicians and policymakers Shorter delays in breast cancer
compared with other cancers may occur because of a more
straightforward presentation of signs and symptoms that are easily
understood by patients and doctors, clear referral guidance, well-
organised secondary care clinics, a national screening programme
and a high public profile. Reductions in delays may improve
survival. Longer delays in prostate cancer may occur because of
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Figure 5 Referral delay.
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sthe insidious onset of nonspecific symptoms, which may occur on
top of preexisting urinary outflow symptoms. Delays may improve
in the future with more opportunistic screening, although the
effect of this on survival is unknown. The long delays in colorectal
cancer may be for similar reasons; again the effects of the
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Figure 6 Secondary care delay.
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Figure 7 Secondary care delay by GP contact.
Table 6 Mean (s.d.) and median (IQR) delays after recoding referral and
secondary care delay
N Number recoded % N Mean (s.d.) Median (IQR)
Referral delay
Colorectal 12884 357 3 51.7 (75.5) 21 (11.56)
Lung 2989 39 1 37.4 (61.2) 21 (5.56)
Ovarian 2504 51 2 41.5 (69.0) 21 (5.56)
Prostate 8121 244 3 59.4 (77.8) 21 (11.56)
NHL 4353 111 3 45.5 (73.5) 21 (5.56)
Breast 17561 159 1 23.9 (44.6) 11 (5.21)
Secondary care delay
Colorectal 13510 266 2 14.9 (32.7) 0 (0.7)
Lung 3237 38 1 13.3 (28.3) 0 (0.7)
Ovarian 2504 30 1 10.6 (26.7) 0 (0.7)
Prostate 7844 173 2 14.7 (33.8) 0 (0.7)
NHL 4141 68 2 15.7 (31.8) 0 (0.21)
Breast 22075 137 1 6.44 (18.5) 0 (0.7)
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sintroduction of a national screening programme are unknown.
While there is insufficient evidence at present to prove that shorter
delays are associated with better prognosis, there is considerable
logic that this should be the case, given the potential for curative
treatments. The effects of these delays for lung cancer, ovarian
cancer and non-Hodgkin’s lymphoma are unclear. There is clear
potential to reduce delays with the anticipated outcome of
improved survival.
The finding that patient and primary care delays were the
longest suggests that while further reductions in referral delays and
secondary care delays may result in better psychological outcomes,
attempts to improve clinical outcomes (earlier stage diagnosis and
improved survival), must be directed at patient and/or primary
care delays.
The percentage of patients with cancer who bypassed their GP in
their diagnostic journey varied considerably between the six
cancers. This may have been for one of two reasons. First, because
of diagnosis by screening. From the literature, it would be expected
that a significant numbers of breast cancers would be screen-
detected (Banks et al, 2004). Our sensitivity analysis showed that
for the female population in the age range for breast cancer
screening, fewer patients saw their GP prior to diagnosis than
those outside the age range, suggesting that screen-detected
cancers were responsible for many of those apparently bypassing
the GP. Second, through secondary care diagnosis following an
emergency admission, by self-presentation to A&E or via an
interspecialty referral. Such patients are likely to have varied
presentations of often very advanced or rapidly progressing (and
symptomatic) disease, and may, to a degree, confound the
findings.
The finding that patients who reported seeing their GP prior to
diagnosis had longer delays than those who did not was an
unexpected finding. Given that the referral delays were not
prolonged, there are two potential explanations of this finding.
Firstly, because earlier stage disease (usually less symptomatic)
presents mainly to primary rather than secondary care, with later
stage disease (with more aggressive symptoms) more likely to be
presented to secondary care. Second, because there may be more
‘system’ delays in primary compared to secondary care (e.g.
waiting times for primary care initiated diagnostics). Shorter
secondary care delays in patients not seeing their GP prior to
diagnosis are probably explained by quicker access to diagnostic
tests for in-patients compared with outpatients. The effect of these
longer diagnostic delays in patients seeing their GP prior to
diagnosis on stage at diagnosis and survival remains unknown.
The differences in delays by diagnostic pathway is an important
finding and needs further work.
The implications of these findings, the methodological limita-
tions notwithstanding are that there are significant opportunities
to reduce diagnostic delay in order to potentially improve clinical
outcomes, at least for at-risk groups for some of these six cancers,
and to potentially reduce psychological distress caused by delays
(Risberg et al, 1996). This is in keeping with the recent National
Audit Office report recommendation to tackle diagnostic delays
(National Audit Office, 2004). However, such interventions must
be considered within the context of the overall presentation of
suspicious symptoms in primary care, and the low positive
predictive symptoms of suspected symptoms, and the processes
of diagnostic reasoning (including watchful waiting) and appro-
priate thresholds for referral as a result. Our findings will provide a
baseline for comparison of future surveys to measure progress in
reducing diagnostic delays.
Unanswered questions and future research Prior to the develop-
ment and evaluation of interventions to reduce delay (Jensen et al,
2002), further work needs to be performed in order to elucidate the
separate contributions of patient and primary care delays to the
overall delays. There may be variation between delays and socio-
demographic factors, and local or regional variations; these need
quantifying prior to intervention. Findings from the ever-
increasing evidence base on the reasons for patient delays in most
cancers, and the smaller evidence base regarding primary care
delays (Spellman et al, 1999) will inform the development of the
interventions. Lastly, work is needed to further explore the reasons
for and implications of longer delays in patients who reported
seeing see their GP prior to diagnosis, compared with those who
did not.
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